Drugs / HD201
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03776240 | Apr → Aug 2019 | — | Prestige Biopharma Limited | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03013504 | Feb 2018 → Apr 2019 | HER2 positive breast carcinoma | Prestige Biopharma Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HD201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03776240 ↗ |
| Route | Intravenous | “Single-dose 6mg/kg body weight by 90 minute intravenous infusion” NCT03776240 ↗ |